Relevant bibliographies by topics / Lü liu zhi nan

Contents

  1. Journal articles
  2. Books

Academic literature on the topic 'Lü liu zhi nan'

Author: Grafiati
Published: 28 July 2024
Last updated: 31 July 2025

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the lists of relevant articles, books, theses, conference reports, and other scholarly sources on the topic 'Lü liu zhi nan.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Journal articles on the topic "Lü liu zhi nan"

1

Lü, Ya-Nan, Xingyue Liu, and Ren Dong. "First record of the fossil snakefly genus Mesoraphidia (Insecta: Raphidioptera: Mesoraphidiidae) from the Middle Jurassic of China, with description of a new species." Zootaxa 3999, no. 4 (2015): 560–70. https://doi.org/10.11646/zootaxa.3999.4.6.

Full text
Abstract:
Lü, Ya-Nan, Liu, Xingyue, Dong, Ren (2015): First record of the fossil snakefly genus Mesoraphidia (Insecta: Raphidioptera: Mesoraphidiidae) from the Middle Jurassic of China, with description of a new species. Zootaxa 3999 (4): 560-570, DOI: 10.11646/zootaxa.3999.4.6
APA, Harvard, Vancouver, ISO, and other styles
2

Lu, Yu-Hang, Sheng-Nan Zhang, Hong-Zhi Du, Ratchadawan Cheewangkoon, and Jian-Kui Liu. "Additions to Crassiparies and Neobrevicollum (Neohendersoniaceae, Pleosporales) associated with woody hosts in Southwest China." Phytotaxa 636, no. 2 (2024): 126–38. https://doi.org/10.11646/phytotaxa.636.2.2.

Full text
Abstract:
Lu, Yu-Hang, Zhang, Sheng-Nan, Du, Hong-Zhi, Cheewangkoon, Ratchadawan, Liu, Jian-Kui (2024): Additions to Crassiparies and Neobrevicollum (Neohendersoniaceae, Pleosporales) associated with woody hosts in Southwest China. Phytotaxa 636 (2): 126-138, DOI: 10.11646/phytotaxa.636.2.2, URL: https://phytotaxa.mapress.com/pt/article/download/phytotaxa.636.2.2/51508
APA, Harvard, Vancouver, ISO, and other styles
3

Liu, Qun, Nan Lin, Dai-Gui Zhang, et al. "Trichosanthes sunhangii (Cucurbitaceae), a new species from Hubei, China." Phytotaxa 479, no. 3 (2021): 287–94. https://doi.org/10.11646/phytotaxa.479.3.5.

Full text
Abstract:
Liu, Qun, Lin, Nan, Zhang, Dai-Gui, Huang, Xian-Han, Wang, Heng-Chang, Yang, Jing- Yuan, Tojibaev, Komiljon, Lv, Zhen-Yu, Deng, Tao, Li, Zhi-Min (2021): Trichosanthes sunhangii (Cucurbitaceae), a new species from Hubei, China. Phytotaxa 479 (3): 287-294, DOI: 10.11646/phytotaxa.479.3.5, URL: http://dx.doi.org/10.11646/phytotaxa.479.3.5
APA, Harvard, Vancouver, ISO, and other styles
4

Xue, Wei-Wei, Huan-Nan Wang, Zhi-Meng Wang, et al. "Cloning and Characterization of ifitm1 and ifitm3 Expression During Early Zebrafish Development - CORRIGENDUM." Zygote 24, no. 1 (2015): 159. http://dx.doi.org/10.1017/s0967199415000398.

Full text
Abstract:
The authors apologise for errors in the corresponding authors details given on page 1 of the article. Below is the correct information of the corresponding author and email address :1) Wei-Wei Xue, Huan-Nan Wang, Zhi-Meng Wang, Meng-Xi Qiu, Jing Che, Feng-Jiao Deng* and Jiang-Dong Liu*2) *All correspondence to: Feng-Jiao Deng and Jiang-Dong Liu. e-mail: fish4@whu.edu.cn3) All authors are from the same one laboratory. The second laboratory was superfluous and should be deleted.
APA, Harvard, Vancouver, ISO, and other styles
5

Huang, Zi-Lu, Zhi-Gang Liu, Qi Lin, et al. "Abstract 5113: Fractionated radiation therapy alters energy metabolism and induces cellular quiescence exit in patient-derived orthotopic xenograft models of high-grade glioma." Cancer Research 84, no. 6_Supplement (2024): 5113. http://dx.doi.org/10.1158/1538-7445.am2024-5113.

Full text
Abstract:
Abstract Radiation is one of the standard therapies for pediatric high-grade glioma (pHGG), of which the prognosis remains poor. To gain an in-depth understanding of the biological activities beyond the classic DNA damage, we treated 6 patient-derived orthotopic xenograft (PDOX) models, including one with DNA mismatch repair (MMR) deficiency, with fractionated radiations (2 Gy/day x 5 days). Extension of survival time was noted in 4/6 PDOX models (P<0.05) and widespread γH2AX positivity in >95% tumor cells in tumor core and >85% in the invasive foci, accompanied by ~30% ap
APA, Harvard, Vancouver, ISO, and other styles
6

Peng, Zhi, Hua Wang, Baorui Liu, et al. "Abstract CT152: A multicenter Phase II study of savolitinib in patients with MET-amplified gastroesophogeal junction adenocarcinomas or gastric cancer." Cancer Research 83, no. 8_Supplement (2023): CT152. http://dx.doi.org/10.1158/1538-7445.am2023-ct152.

Full text
Abstract:
Abstract Background: MET gene amplification is associated with poor prognosis in gastric cancer (GC) and gastroesophageal junction adenocarcinomas (GEJ). Savolitinib is a potent and highly selective oral MET tyrosine-kinase inhibitor. Here we reported the preliminary efficacy and safety from a phase 2 trial of savolitinib monotherapy in patients (pts) with MET-amplified advanced or metastatic GC/GEJ. (NCT04923932). Methods: Eligible pts had 2L+ GEJ or GC, with MET amplification and measurable lesions. Pts received savolitinib at 600 mg QD for body weight (BW) ≥50 kg, while 400 mg QD for BW &am
APA, Harvard, Vancouver, ISO, and other styles
7

Xu, Rui-Hua, Dan-Yun Ruan, Rong-Bo Lin, et al. "Abstract CT010: Phase I dose-escalation and expansion study of JS107, a claudin 18.2 (CLDN18.2)-targeting antibody-drug conjugate (ADC), as monotherapy or in combination for patients (pts) with advanced solid tumors." Cancer Research 85, no. 8_Supplement_2 (2025): CT010. https://doi.org/10.1158/1538-7445.am2025-ct010.

Full text
Abstract:
Abstract Background: JS107 is a monomethyl auristatin E conjugated, CLDN18.2 specific ADC. JS107 exhibited potent anti-tumor activities in preclinical studies with a tolerable safety profile. Here we report the safety and efficacy results of JS107 monotherapy or in combination for pts with advanced solid tumors from the first-in-human phase 1 trial (NCT05502393). Methods: In Part A of the study, pts with advanced solid tumors refractory to standard therapies were treated with JS107 at 0.15-3.5 mg/kg Q3W during dose escalation and CLDN18.2+ pts were treated with JS107 at 2.0 and 3.0 mg/kg Q3W d
APA, Harvard, Vancouver, ISO, and other styles
8

Chen, Li, Shu-hao Jiang, Guang-Yu Liu, et al. "Abstract P2-11-06: Neoadjuvant chemotherapy plus camrelizumab vs. chemotherapy in patients with locally advanced immunomodulatory triple-negative breast cancer: a prospective, randomized, open-label, phase 2 trial." Clinical Cancer Research 31, no. 12_Supplement (2025): P2–11–06—P2–11–06. https://doi.org/10.1158/1557-3265.sabcs24-p2-11-06.

Full text
Abstract:
Abstract Background: Blockade of the PD-L1/programmed cell death protein 1 checkpoint improves the efficacy of classical chemotherapy in the neoadjuvant treatment of triple-negative early breast cancer (TNBC) but results in adverse events. Treatment approaches for immune-sensitive diseases and the efficacy of adding camrelizumab to chemotherapy regimens is unclear, especially in TNBC patients with a high tumor burden. Methods: This open-label, randomized, phase 2 study randomly assigned (1:1) 90 patients ≥ 18 years with stage II–III histologically documented immunomodulatory TNBC (CD8 ≥10%) we
APA, Harvard, Vancouver, ISO, and other styles
9

Li, Junjie, Zhong-Hua Wang, Li Chen, et al. "Abstract GS1-04: HER2-Directed Antibody-Drug Conjugate SHR-A1811 in the Neoadjuvant Treatment of HER2-positive Early Breast Cancer: a Prospective, Randomized, Open-label, Phase 2 Trial." Clinical Cancer Research 31, no. 12_Supplement (2025): GS1–04—GS1–04. https://doi.org/10.1158/1557-3265.sabcs24-gs1-04.

Full text
Abstract:
Abstract Background: Standard neoadjuvant regimens for HER2 positive breast cancer include trastuzumab and pertuzumab combined with chemotherapy. No data has been reported for the efficacy and safety of HER2-direted Antibody-drug conjugate (ADC) monotherapy or combined with Tyrosin kinase inhibitor (TKI) in the neoadjuvant setting. We assessed the antitumor activity and safety of a novel ADC SHR-A1811 in neoadjuvant treatment of HER2+ breast cancer. Methods: This open label, randomized, phase 2 study enrolled 265 HER2 positive patients, aged 18 years or older with stage II–III disease. Patient
APA, Harvard, Vancouver, ISO, and other styles
10

Gonçalves, Gabriela Sumie Yaguinuma, Tayna Natsumi Takakura, Anderson Catelan, Rosalinda Tanuri Zaninotto Venturim, Carolina dos Santos Santinoni, and Christine Men Martins. "Tratar ou extrair? Tratamento de lesão endoperiodontal, um relato de caso clínico." ARCHIVES OF HEALTH INVESTIGATION 9, no. 6 (2020): 535–40. http://dx.doi.org/10.21270/archi.v9i6.4814.

Full text
Abstract:
Introdução: Lesões endoperiodontais são lesões originadas de produtos inflamatórios encontrados tanto em periodonto quanto em polpa. Tais lesões podem se originar devido a uma infecção pulpar ou periodontal. Visando o prognóstico favorável, é imprescindível o conhecimento da etiologia, realização do correto diagnóstico e elaboração do plano de tratamento que envolve o tratamento endodôntico precedido do tratamento periodontal. Objetivo: O propósito do presente trabalho foi de relatar um caso clínico de lesão endoperiodontal e o tratamento realizado. Relato de caso clínico: Paciente gênero femi
APA, Harvard, Vancouver, ISO, and other styles

Books on the topic "Lü liu zhi nan"

1

ping, Li jin, and Hong yun. Wu ye guan li yi nan you wen bi da. Zhong guo dian li chu ban she, 2007.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
2

Li, Xiandong. Wu ye jiu fen fa lü jie jue zhi nan. Ji xie gong ye chu ban she, 2004.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
3

Wenling, Luo, ed. Liu chao seng lü shi yan jiu: Nan chao shi ge yu fo jiao guan xi zhi yan jiu. Hua Mulan wen hua chu ban she, 2009.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
4

li, Sun mao. Wei fan gong an xing zheng guan li xing wei ming chen shi yi yu shi wu zhi nan. Zhong guo ren min gong an ta xue chu ban she, 2011.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
5

Gong an bu. jiao tong guan li ju. Zhong hua ren min gong he guo dao lu jiao tong an quan fa shi yong zhi nan. Zhong guo ren min gong an ta xue chu ban she, 2003.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
6

feng, Yang min. 2015 nian shang biao dai li ren shui ping ce shi ying shi zhi nan. Fa lü chu ban she, 2015.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
7

dong, Zhang xiao, Zhai ji guang, and Yi yun he. Zhong hua ren min gong he guo qi ye suo de shui fa shi shi tiao l shi yi yu shi yong zhi nan ji an li jing jie. Li xin hui ji chu ban she, 2007.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
8

Kedong, Hu, ed. Xi nan zhi lü. Chengdu di tu chu ban she, 2001.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
9

Qiushi, Lu, ed. Liu bing zhi lü. Wen hui chu ban she, 2009.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
10

Shu, Hui. Piao liu zhi lü. Chong wen shu ju, 2007.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
More sources
You might also be interested in the extended bibliographies on the topic 'Lü liu zhi nan' for particular source types:
Books
We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!

To the bibliography